Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEP-COVID: Full-dose vs. prophylactic LMWH in high-risk COVID-19
NCT04401293Phase 3Completed
- Sponsor
- Northwell Health
- Start
- Apr 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by Northwell Health. Started Apr 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04401293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401293.